Position:Home > Phexcom News >
-
Influential cancer group rolls out first set of 'affordability' ratings on cancer drugsStruggling Daiichi plots another 1,000-plus job cuts in U.S. October 19, 2015 | ByTracy Staton SHARE Tweet TOOLS Comment Print Contact Author Reprint Daiichi Sankyo's2015/10/20
-
Valeant posts 36% growth amid pricing scrutiny; may sell neurology bizValeant posts 36% growth amid pricing scrutiny; may sell neurology biz October 19, 2015 | ByCarly Helfand SHARE Tweet TOOLS Comment Print Contact Author Reprint Valea2015/10/20
-
Pharma's newest nemesis? Nestlé works at the intersection of food and drugs to attack illnessesPharma's newest nemesis? Nestlé works at the intersection of food and drugs to attack illnesses Swiss food company talks turkey with the FDA even as it researches conditions like Alzheimer's Octob2015/10/19
-
Pfizer responds to FiercePharmaPfizer responds to FiercePharma October 16, 2015 SHARE Tweet TOOLS Comment Print Reprint Tracy Staton wrote anarticle on Thursday,based onthis pieceinForbes. Pfizer took excepti2015/10/19
-
Boehringer looks for Pradaxa boost from now FDA-approved antidoteBoehringer looks for Pradaxa boost from now FDA-approved antidote October 16, 2015 | ByCarly Helfand SHARE Tweet TOOLS Comment Print Contact Author Reprint The lack of an antid2015/10/19
-
Advera: AbbVie's Viekira Pak riskier than Gilead's Harvoni for hep CAdvera: AbbVie's Viekira Pak riskier than Gilead's Harvoni for hep C October 15, 2015 | ByEmily Wasserman SHARE Tweet TOOLS Comment Print Contact Author Reprint Vieki2015/10/16
-
FDA swats down Pfizer's Xeljanz in plaque psoriasisFDA swats down Pfizer's Xeljanz in plaque psoriasis October 15, 2015 | ByCarly Helfand SHARE Tweet TOOLS Comment Print Contact Author Reprint Pfizer ($PFE) will have to2015/10/16
-
FDA's review of BI's Pradaxa was 'lax' and 'permissive,' watchdog claimsFDA's review of BI's Pradaxa was 'lax' and 'permissive,' watchdog claims October 15, 2015 | ByCarly Helfand SHARE Tweet TOOLS Comment Print Contact Author Reprint Boehringer In2015/10/16
-
J&J says it has plenty of firepower for M&A, buyback or no buybackJ&J says it has plenty of firepower for M&A, buyback or no buyback October 14, 2015 | ByCarly Helfand SHARE Tweet TOOLS Comment Print Contact Author Reprint Johnson &am2015/10/15
-
Allergan plots 117 job cuts in the wake of Kythera buyoutAllergan plots 117 job cuts in the wake of Kythera buyout October 14, 2015 | ByTracy Staton SHARE Tweet TOOLS Comment Print Contact Author Reprint The job-cutting ax has been h2015/10/15